Background: Highly active antiretroviral therapy (HAART) for pregnant HIV-positive women reduces the risk of mother-to-child transmission, but is associated with an increased risk of preterm delivery (<37 weeks gestation). We aimed to quantify the incremental risk-benefit ratio for HAART compared with zidovudine monotherapy with respect to these outcomes. 
The use of antiretroviral therapy in pregnancy substantially reduces the risk of mother-to-child HIV transmission (MTCT). In 1994, zidovudine was shown in the AIDS Clinical Trial Group 076 trial to reduce the risk of transmission by two-thirds in the intervention arm (8%) compared with the untreated control arm (25%), when taken in pregnancy and at delivery, and administered to the infant for the first 6 weeks of life [1] . Transmission rates in observational studies of non-breastfeeding women receiving zidovudine in the mid-1990s ranged from 4 to 10% [2] [3] [4] . The risk of MTCT can be further reduced by the use of highly active antiretroviral therapy (HAART), which consists of three or more antiretroviral drugs, usually from at least two different classes; although there have been no clinical trials of HAART in pregnancy, transmission rates of 1-2% have been reported in large observational studies [3, [5] [6] [7] .
Despite the benefits of HAART, evidence suggesting an association with preterm delivery has emerged, and concerns about other adverse effects in pregnancy and early life have been raised [8] . A number of European studies demonstrated an increased risk of preterm delivery associated with combination antiretroviral therapy in comparison with less complex regimens [9] [10] [11] [12] [13] , and a putative mechanism involving pregnancy-and HIVrelated changes in the cytokine environment has been suggested [14] . Although some studies from the US have not observed this association [15, 16] , others have reported a link with protease inhibitor-based HAART [17, 18] . More recently, a study in Côte d'Ivoire demonstrated an increased prevalence of low birth weight in infants exposed to HAART, compared with those exposed to zidovudine in an earlier time period [19] . Although information on gestational age was not Introduction available in the Côte d'Ivoire study, this observation was probably driven by preterm delivery. Indeed, findings from the French Perinatal Cohort suggest that HAART is not associated with a low birth weight z-score (that is, birth weight adjusted for gestational age) [20] .
Concerns about adverse effects in pregnancy have provided the rationale for reducing HAART exposure where possible. British guidelines suggest that zidovudine monotherapy can be used for prevention of MTCT (combined with elective caesarean section delivery) for women who do not need HAART for their own health and have a baseline HIV RNA plasma viral load of <10,000 copies/ml [21] . This approach appears to be effective, with no transmissions occurring among the 468 women who received zidovudine monotherapy and delivered by elective caesarean section between 2000 and 2006 in the UK and Ireland [7] .
Quantification of the risks and benefits of HAART in pregnancy can inform the debate about optimal management of HIV infection in pregnancy, and has been explored using decision analysis to investigate the risks of mitochondrial toxicity, another possible HAARTassociated side effect, in an African context [22] . Alternatively, probabilistic simulation modelling has been proposed as a method for simultaneously estimating the risks and benefits of treatment and uncertainty around them [23, 24] . In this paper, we estimate the risk-benefit ratio for HAART in pregnancy in terms of preterm delivery and MTCT at a population level, based on UK and Ireland surveillance data, and use Monte Carlo simulation methods to quantify the joint variability around the estimates.
Methods
We used a two-stage probabilistic simulation approach for risk-benefit analysis. The first stage involved obtaining estimates of the risk and benefit probabilities by treatment. In the second stage, Monte Carlo methods were used to simulate from the probability distributions, thus propagating the uncertainties around the estimates.
Model estimates
Estimates of preterm delivery and MTCT were based on data from the National Study of HIV in Pregnancy and Childhood (NSHPC), an ongoing, comprehensive, active surveillance study of pregnancies in HIV-positive women in the UK and Ireland (London Multi-Centre Research Ethics Committee approval, 2004, MREC/04/2/009) [7, 11] . Logistic regression analyses were carried out in Stata version 10.0 (StataCorp LP, College Station, TX, USA). Full study methodology and details of similar analyses are described elsewhere [7, 11] . HAART was defined as three or more antiretroviral drugs.
Preterm delivery estimates were adapted from previous NSHPC analyses [25, 26] . Deliveries at <37 weeks gestation were defined as preterm and those at <32 weeks gestation as severely preterm [27] . Logistic regression models for the association between antiretroviral therapy and preterm delivery were fitted, adjusting for year of delivery, maternal ethnicity (White, Black or other), region of birth (UK/Ireland or elsewhere), injecting drug use (as the source of HIV acquisition) and clinical status (asymptomatic or HIV-related symptoms). As there was no change over time in preterm delivery rates among women on monotherapy (trend test, P=0.47) or on HAART (P=0.12), all pregnancies occurring between 1990 and 2006 were included.
MTCT rates were derived specifically for these analyses; although transmission rates in this population have been previously published [7] , the appropriate comparisons required for these analyses have not been presented. In order to estimate the effect of HAART relative to zidovudine monotherapy at a population level (that is, assuming that all infected pregnant women are treated with either HAART or monotherapy regardless of other factors), the association between treatment type and MTCT was explored by comparing births to women on HAART at any time between 1996 and 2006 with those to women on monotherapy before 1998, when HAART was uncommon (only five cases between 1996 and 1997). Births to women on monotherapy since 1998 were excluded because of the selective use of this treatment in recent years for women who did not require HAART for their own health and delivered by elective caesarean section. Logistic regression models were adjusted for mode of delivery (elective caesarean section, emergency caesarean section or vaginal delivery), gestational age (categorized as ≥37 weeks, 35-36 weeks, 32-34 weeks or <32 weeks) and sex of the child. Because of the differences in time periods between the preterm delivery and MTCT analyses, it was not possible to use a common dataset for risk and benefit estimates.
For the baseline scenario, observed preterm delivery and MTCT rates in women on monotherapy were used. To estimate rates in the HAART group, adjusting for confounders, the definition of an odds ratio (OR) used was OR=(p 1 
, where p 0 is the rate in the unexposed or baseline group, and p 1 is the rate in the exposed group [28] . Adjusted preterm delivery and transmission rates for the HAART group were derived by solving the equation for p 1 and substituting the adjusted odds ratio (AOR) estimated in logistic regression models for the OR, as follows:
Incremental risk-benefit ratio
Incremental risks and benefits were calculated as p 1 -p 0 (rate in HAART-exposed women minus rate in monotherapy-exposed women); ∆R=R 1 -R 0 denoted incremental risks, where R 1 corresponded to the risk in the exposed group and R 0 to the risk in the baseline group; ∆B=B 0 -B 1 denoted incremental benefits, where B 0 corresponded to the benefit in the baseline group and B 1 to the benefit in the exposed group [23] . The incremental risk-benefit ratio (IRBR) is defined as:
Monte Carlo simulation
Calculating confidence intervals (CIs) for IRBRs is problematic because ratios can be negative and tend to be non-normally distributed [29] ; therefore, in order to incorporate (simultaneously) the uncertainty from the risk and benefit estimates, Monte Carlo methods similar to those suggested by Lynd and O'Brien [23] were used to simulate the joint probability densities of incremental benefit (MTCT) and incremental risk (preterm/severe preterm delivery). Values for proportions of both preterm delivery and MTCT were generated from appropriate beta probability density functions [30] in order to account for the fact that normality cannot always be assumed when calculating CIs around proportions [23] . To model the uncertainty relating to the AOR, the estimate of its natural logarithm, that is ln(AOR), was used because it tends to be normally distributed. Analyses were carried out in R version 2.8.0 (R Foundation for Statistical Computing, Vienna, Austria) [31] . The simulations consisted of repeatedly sampling from the assumed parameters' distributions by randomly selecting values from the beta distributions for the baseline proportions and from the normal distributions for ln(AOR), using the algorithm shown in Figure 1 .
A value for the baseline risk ( 0 , denoting sampled R 0 ) was sampled from the distribution of preterm delivery for monotherapy-exposed women, and a value for the baseline benefit ( 0 ) was sampled from the MTCT distribution for monotherapy-exposed women. This was replicated 5,000 times in order to simulate the joint uncertainty around the estimates.
The distribution of ln(AOR) for the risks and benefits was also randomly sampled 5,000 times, and rates for the HAART group ( 1 and 1 ) were calculated from Equation 1 using the point estimates for risk and benefit rates in the baseline group (R 0 and B 0 ), and the ln(AOR) s.
For each of the 5,000 realizations, the incremental risk ( 1 -0 ) and benefit ( 0 -1 ) were calculated, and the IRBR was computed. The distribution of the IRBR was thus approximated.
The same random number seed was fixed at the start of each simulation to enable simulations to be replicated. Simulation intervals were obtained by approximating the 2.5% and 97.5% quantiles of the distributions generated in the simulation.
Assumptions
Adverse effects other than preterm delivery, such as maternal drug-related toxicity, the effect of mode of delivery or paediatric outcomes (such as mitochondrial toxicity or anaemia) were not considered in these models. Benefits other than the effect on MTCT, for instance, slowing of maternal disease progression, were also omitted. Although AORs were used in the simulation to control for other potential risk factors, baseline rates related to the population of HIV-infected pregnant women in the UK and Ireland. Furthermore, these models assumed a homogeneous population, and differential effects within population subgroups were ignored.
Sensitivity analyses
Although some studies have shown an increased risk of transmission in preterm infants, prematurity was not an independent risk factor for MTCT among women on HAART in this population [7] ; however, the effect of an association between preterm delivery and MTCT was investigated in a sensitivity analysis. Models were adapted by incorporating a relative risk, varying from 1 to 4, for the increase in MTCT resulting from preterm delivery; details of this methodology are available elsewhere [25] .
Results

Risk and benefit estimates
Estimates for preterm delivery rates were obtained from previous analyses [25, 26] and are shown in Table 1 . HAART was associated with a 1.43-fold increased odds of preterm delivery (95% CI 1.10-1.86; P=0.01) compared with monotherapy among women exposed between 1990 and 2006, after adjusting for year of delivery, maternal ethnicity, region of birth, injecting drug use and clinical symptoms [26] . This effect did not vary according to inclusion of a protease inhibitor (AOR 1.42 versus 1.45 for HAART without protease inhibitor). Estimates for MTCT rates were obtained from logistic regression models. HAART was associated with an 87% reduction in MTCT compared with pre-1998 monotherapy (AOR 0.13, 95% CI 0.06-0.27; P<0.001; n=4,319) after adjusting for mode of delivery, gestational age and sex (Table 1) . Among women on monotherapy, the rate of MTCT did not vary significantly by year or by maternal HIV symptoms. Although B 0 , benefit in baseline group; B 0 , sampled benefit in baseline group; B 1 , sampled benefit in exposed group; HAART, highly active antiretroviral therapy; ln(AOR), natural logarithm of the adjusted odds ratio; MTCT, mother-to-child transmission; R 0 , risk in baseline group; R 0 , sampled risk in baseline group; R 1 , sampled risk in exposed group. Estimates were obtained from the same dataset as that used in Townsend et al. [7] , but with the exclusion of births to women on monotherapy since 2000 (n=638), and the addition of births to women on monotherapy before 1998 (n=172) or HAART before 2000 (n=162).
d AOR based on comparison of HAART at any time (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) with monotherapy in the pre-HAART era (before 1998). AOR adjusted for mode of delivery, gestational age and sex. B 0 , benefit in baseline group; CI, confidence interval; R 0 , risk in baseline group; R 1 , risk in exposed group. the transmission rate in this analysis was higher in severely preterm infants (<32 weeks gestation) than in full-term infants (6.7 versus 2.7%), there was no statistically significant association in the multivariable analysis (AOR 1.14 for severe preterm versus full-term, 95% CI 0.26-5.08; P=0.86). The beta probability distributions used to model baseline preterm delivery and MTCT rates are shown in Figure 2 .
Incremental risk-benefit ratio
The incremental benefit associated with exclusive HAART (versus exclusive monotherapy) was a reduction in MTCT of 6.0% (∆B=7.0%-1.0%), and the incremental risk was an increase in preterm delivery of 3.8% (∆R=14.0%-10.2%) for preterm and 1.4% for severe preterm delivery (∆R=2.8%-1.4%). The estimated IRBR (from Equation 2) was 0.63 preterm infants and 0.23 very preterm infants per HIV infection averted.
Simulation
The joint probability densities of preterm delivery and MTCT are shown in Figure 3A . A clear difference between the two treatment groups is apparent. The simulation was repeated for severe preterm delivery and a similar pattern was observed ( Figure 3B ). The incremental risk-benefit pairs were then computed using the simulated rates. The median risk-benefit ratios were 0.65 preterm and 0.25 very preterm infants for each HIV infection averted. Although these values were very close to the point estimates (0.63 and 0.23, respectively), the means tended to be higher (0.74 and 0.29, respectively) because of the right-skewed distribution of the ratios. Figure 4 shows the incremental risks and benefits for the simulations on a risk-benefit plane, with the x-axis representing the difference in the probability of MTCT (∆B) occurring with HAART relative to monotherapy, and the y-axis representing the difference in the probability of preterm or severe preterm delivery (∆R). The red and blue lines in Figure 4 correspond to acceptability thresholds (µ), or the number of adverse events we would be willing to accept for one additional beneficial event. At the line µ=1, one additional premature birth would be acceptable in order to prevent one additional transmission. This condition is only satisfied for the points lying below this line; thus, the proportion of points below the line estimates the probability that the condition (each beneficial event corresponding to one adverse event) is satisfied. These lines can also be used to indicate confidence limits; the upper and lower red lines indicate the limits between which 95% of the points fall, and correspond to µ=0.06 and µ=1.96 in the preterm delivery model, and µ=-0.02 and µ=0.88 in the severe preterm delivery model. In the preterm delivery model, 95% of the points fall below the line with slope µ=1.60; the corresponding line for the severe preterm delivery model has a slope of µ=0.74. There is, therefore, a 95% chance that for each transmission avoided, the maximum number of additional preterm infants would be 1.60 and the maximum number of severely preterm infants would be 0.74.
Sensitivity analyses
Modelling up to a fourfold increased risk of transmission associated with preterm delivery produced only a small shift in the joint densities. The IRBRs did not change and CIs varied only marginally compared with the unadjusted model [25] . 
Discussion
Although awareness of the risks associated with any treatment is important, these must be considered in relation to the corresponding benefits in order for conclusions about the value of that treatment to be made. A risk-benefit model based on two-stage Monte Carlo methods was developed to enable the observed risks of preterm delivery to be quantified in relation to the main benefit of HAART in pregnancy, a reduced risk of MTCT. Comparison was made between HAART (any time) and zidovudine monotherapy in the pre-HAART era because use of monotherapy in recent years was restricted to women with a low baseline risk of transmission. This comparison enabled the full extent of the benefits associated with HAART to be quantified at a population level in the context of the reported risks.
These results, which were based on national surveillance data from the UK and Ireland, suggest that avoiding 100 transmissions by using HAART rather than monotherapy would result in an additional 63 preterm births (95% CI 6-196), 23 of which would occur before 32 weeks gestation (95% CI -2-88), assuming a 1.4-and 2-fold increase in the risk of preterm and severe preterm delivery, respectively, and a 7-fold decrease in the risk of MTCT associated with HAART. These findings were not affected by allowing for an increased risk of transmission among preterm infants, as demonstrated in a sensitivity analysis.
Interpretation of these findings depends on the choice of acceptability threshold, that is, how many preterm deliveries, and particularly severe preterm deliveries, are we willing to accept in order to prevent one perinatal transmission? In this UK and Ireland context, if these outcomes were equal in severity, HAART would be considered superior to exclusive monotherapy because more infants avoid infection with this approach than are born prematurely. However, further information is required to determine an appropriate risk-benefit acceptability threshold for these outcomes. Preterm delivery is associated with a significantly increased risk of perinatal morbidity and mortality, although this is generally confined to very premature infants [32] . HIV infection has serious lifelong consequences, however, and ultimately results in progression to AIDS and death. Although the advent of effective antiretroviral drugs has improved prognosis for HIV-infected children in resource-rich countries, complications relating to toxicity or resistance might arise [33, 34] . The appropriate balance of risks and benefits will probably vary by population and healthcare setting. In resource-poor countries, both premature birth and HIV infection will be associated with higher rates of paediatric morbidity and mortality than in resource-rich settings, and the relative consequences and costs of these outcomes will differ according to the quality of neonatal care facilities and availability of antiretroviral therapy. Population-specific information on outcomes in preterm and HIV-infected children would ideally be factored into decisions regarding the acceptable risk-benefit threshold. Finally, attitudes and preferences of both clinicians and patients towards different perinatal outcomes, which might be affected by the continued stigma of HIV, could also influence decision making.
These findings relate to a population level approach assuming that either monotherapy or HAART was used for all pregnant women. In practice, the range of treatments currently available means that in resource-rich countries, decisions on the type and timing of treatment can be based on individual clinical and immunological factors, desired mode of delivery and additional factors, such as past treatment experience and patient preference. Consequently, zidovudine monotherapy is now usually reserved for women with favourable baseline characteristics who do not require HAART for their own health [21, 35] . Among pregnant women in the UK and Ireland, the MTCT rate in women on zidovudine monotherapy who delivered by elective caesarean section (0%, 95% CI 0-0.8) was not significantly different from those among women on HAART who had a planned vaginal delivery (0.7%) or elective caesarean section (0.7%; P=0.15) [7] . With no significant difference in benefits, the reduced risk of preterm delivery associated with zidovudine monotherapy would suggest that this is an appropriate approach for preventing MTCT in this particular group of women who do not require HAART for their own health and deliver by elective caesarean section. Other factors, such as the risk of obstetric complications associated with different modes of delivery, might also need to be considered [36] . Because there have been no clinical trials of HAART in pregnancy, we used observational data from a large prospective surveillance study in the UK and Ireland to assess the odds of preterm delivery and MTCT associated with type of antiretroviral therapy. We used AORs to derive risk and benefit rates associated with HAART, which were adjusted for potential confounding. In a previous analysis of antiretroviral therapy and preterm delivery, we demonstrated that adjusting for maternal HIV-related symptoms or CD4 + T-cell count, in order to account for possible bias in indication for treatment by type of therapy (monotherapy or dual therapy versus HAART), did not substantially alter the association between HAART and preterm delivery [11] . Furthermore, the association between therapy and preterm delivery was of similar magnitude in 1994-1999 as in 2000-2005, despite potential changes over time in other (unmeasured) risk factors for preterm delivery. The effect estimates used in this analysis were adjusted for year of delivery, as well as for maternal HIV symptoms and demographic factors (ethnicity, region of birth and injecting drug use). Adjusting for year of delivery did not substantially alter the association between HAART and preterm delivery, suggesting that the observed association is unlikely to be the result of bias in treatment groups produced by changes over time in other risk factors for preterm delivery. Although the use of zidovudine monotherapy prior to 1998 might have been more common among women with more advanced HIV disease, particularly in earlier years, the MTCT rate in this group did not vary by year or maternal clinical status and was consistent with other reported rates [2] [3] [4] . Another limitation of this analysis is that we were unable to consider duration of HAART because of limited statistical power to detect a difference in preterm delivery rates according to trimester of exposure [11] . Determining optimal timing of initiation of HAART depends both on the potential for adverse effects and on the risk of MTCT, which is strongly associated with duration of treatment in pregnancy [6, 7] . Further limitations of these surveillance data are discussed in detail elsewhere [7, 11] . The 95% simulation intervals around the riskbenefit ratios were relatively wide, partly because the estimate of MTCT among women on monotherapy was based on only 172 women. Although we built our models using data from one population, estimates based on a summary of aggregated published data could be used, potentially resulting in tighter simulation intervals around the risk-benefit ratios.
In conclusion, we have estimated that the use of HAART in pregnancy at a population level would result in 63 (95% CI 6-196) additional preterm deliveries, 23 (95% CI -2-88) at <32 weeks gestation, for every 100 infections prevented, compared with the use of zidovudine monotherapy. However, among women who do not require treatment for their own health, monotherapy can be highly effective in reducing MTCT when combined with elective caesarean section delivery [7] . Further research is needed to clarify the optimal approach for preventing MTCT in this group of healthier women.
